Gilead Ditches Double-Patenting Claim In Tamiflu Suit

Law360, New York (December 21, 2012, 5:40 PM EST) -- A New Jersey federal judge ruled Friday that Gilead Sciences Inc. did not unlawfully extend a patent for its flu drug Tamiflu, squashing generics maker Natco Pharma Ltd.'s bid to invalidate the patent in an attempt to market a generic version.

Natco argued that Gilead's U.S. Patent Number 5,763,483 unfairly extended an earlier patent — U.S. Patent Number 5,952,375 — that the pharmaceutical obtained for Tamiflu, and hence was invalid. But U.S. District Judge Susan D. Wigenton said the '483 patent was issued due to a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.